Ready To Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
Or call (215) 966-6061
MEMBRANE PROTEOME ARRAY
Assess specificity and off-target binding of your biotherapeutic candidates. De-risk your program and choose the right lead molecule.
Is your antibody therapy firing at the right target?
Mistargeted therapies can cause serious side effects and clinical failures.
The Membrane Proteome Array is the leading solution for antibody specificity profiling. This cell-based array contains the largest set of human membrane proteins assembled to determine specificity and preclinical safety of antibodies, CAR-T cell therapies, and other biotherapeutics.
The leading solution for antibody specificity profiling
What makes the Membrane Proteome Array so successful?
6,000 membrane proteins representing ~95% of the membrane proteome
High sensitivity flow cytometry detection, using unfixed cells to ensure native protein conformation and prevent false positives and negatives
Compatible with all biotherapeutics including monoclonal antibodies, scFv, VHH, bispecifics, peptides, and CAR-T cell therapies
4-week turnaround for IND-ready data package with option for full traceability and auditability
Successfully screened 1,000+ molecules
Target validation by titration analysis
Developing CAR-T therapeutics?
MPA offers 3 ways to screen for off-target interactions
Off-target binding of CAR-T cell therapies can kill the wrong cells and result in severe or even life-threatening adverse events. We offer 3 specificity profiling services to assess CAR-T in vitro toxicology, including receptor binding via scFv, binding of CAR-T cells, or functional screens to assess cell killing or markers of T-cell activation.
“MPA technology quickly provided us with the reassurance that Abound Bio’s potent neutralizing antibodies to SARS-CoV-2 did not bind off-target human membrane proteins, which could be associated with toxicity.”
What specificity data do you need for IND applications?
- IND applications require assessment of off-target binding
- Tissue cross-reactivity studies (TCR) have been traditionally employed for off-target screening
- FDA guidelines suggest the use of alternative and newer technologies in lieu of TCR as these become available
What will your data package include?
“We have been very pleased with the data that we obtained from the Membrane Proteome Array platform. This showed that our antibodies recognize only their select target, and not other membrane proteins in their panel.
What else can the Membrane Proteome Array provide?
Antibody Deorphaning Services
Screen your antibody of unknown specificity to identify which protein(s) on the MPA your MAb binds.
Functional Screening for Target Discovery
Discover new therapeutic targets by functional screening of the MPA in live cells
Featured Case Studies
See how FairJourney established that their antibodies do not demonstrate off-target binding
Understand how a MAb can cross-react with a completely unrelated protein
Learn how the Membrane Proteome Array was used to deorphan panels of antibodies with unknown targets
Frequently Asked Questions
A typical MPA project takes 4 weeks from receipt of your antibodies.
The Membrane Proteome Array uses the largest membrane protein library ever assembled, flow cytometry, and unfixed cells for high-sensitivity detection, resulting in the broadest screens and the highest success rates. A typical project involves:
- 1. You send us 500 µg of each antibody that you would like screened
- 2. We optimize conditions for detecting antibody binding in our high-throughput system
- 3. We screen your antibodies on the Membrane Proteome Array under optimized conditions
- 4. We confirm all identified targets in a second flow cytometry titration experiment
- 5. You receive a detailed report within 4 weeks containing the membrane protein binding profiles of your antibodies, the identity of validated targets, and publication-quality figures
You will receive a detailed report containing the binding profiles of your antibodies and results from a second validation screen (antibody titration screen) on any identified targets. The report contains publication-quality figures. Additional publication, patent, and IND filing support is available on request.
The MPA is very flexible regarding screening conditions. Typically, we screen under unfixed conditions, but can use permeabilizing or even serum-free conditions if needed. We will discuss the best conditions for your antibodies with you at the start of your project.
Hits are validated by testing serial dilutions of your antibodies for binding to cells over-expressing identified target(s) in a second flow cytometry experiment. This validation screen is included as part of every project.
